A new vaccine strategy inducing antibodies capable of blocking interaction among disease-causing proteins may offer a safe and effective approach against respiratory syncytial virus (RSV).
A new vaccine strategy inducing antibodies capable of blocking interaction among disease-causing proteins may offer a safe and effective approach against respiratory syncytial virus (RSV).